Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Aug;32(8):1231–1236. doi: 10.1128/aac.32.8.1231

Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections.

M G Bergeron 1, J Mendelson 1, G K Harding 1, L Mandell 1, I W Fong 1, A Rachlis 1, R Chan 1, S Biron 1, R Feld 1, N B Segal 1
PMCID: PMC172383  PMID: 3056255

Abstract

In a prospective, randomized, multicenter study, the efficacy and safety of cefoperazone and the combination ampicillin-tobramycin as initial therapy for patients with severe acute biliary tract infections were compared. Of 77 patients initially entered in the study, definite severe biliary tract infection was confirmed in 67. Sixty-four patients completed treatment. At the end of treatment, 35 of 36 (97%) patients given cefoperazone and 23 of 28 (82%) given ampicillin-tobramycin were cured of their infection (P = 0.07). Pathogens were recovered from the bile in 32 patients; microbiological cures were observed in 18 of 19 (94%) patients receiving cefoperazone and 8 of 13 (62%) receiving ampicillin-tobramycin (P = 0.03). Thirteen patients had septicemia. None (0%) of the eight septicemic patients from the cefoperazone group, but two of five (40%) from the ampicillin-tobramycin group, were clinical failures. Of the isolated pathogens, 51% were resistant to ampicillin, while the resistance rate was 4% for tobramycin and 1% for cefoperazone (P less than 0.001). Biliary concentrations of cefoperazone were maintained at high levels--236 +/- 87 micrograms/ml up to 12 h after administration. Even in the presence of severe obstruction, cefoperazone levels in the bile and gallbladder wall were above MICs for most pathogens. Cefoperazone may be considered as an excellent alternative in the therapy of severe biliary tract infections.

Full text

PDF
1231

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AYLIFFE G. A., DAVIES A. AMPICILLIN LEVELS IN HUMAN BILE. Br J Pharmacol Chemother. 1965 Feb;24:189–193. doi: 10.1111/j.1476-5381.1965.tb02094.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bevan P. G., Williams J. D. Rifamide in acute cholecystitis and biliary surgery. Br Med J. 1971 Jul 31;3(5769):284–287. doi: 10.1136/bmj.3.5769.284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chock E., Wolfe B. M., Matolo N. M. Acute suppurative cholangitis. Surg Clin North Am. 1981 Aug;61(4):885–892. doi: 10.1016/s0039-6109(16)42486-2. [DOI] [PubMed] [Google Scholar]
  4. Claesson B., Holmlund D., Mätzsch T. Biliary microflora in acute cholecystitis and the clinical implications. Acta Chir Scand. 1984;150(3):229–237. [PubMed] [Google Scholar]
  5. De Ritis F., Scioli C. Treatment of biliary infections with ampicillin and hetacillin. Chemotherapy. 1968;13(1):42–53. doi: 10.1159/000220529. [DOI] [PubMed] [Google Scholar]
  6. Dooley J. S., Hamilton-Miller J. M., Brumfitt W., Sherlock S. Antibiotics in the treatment of biliary infection. Gut. 1984 Sep;25(9):988–998. doi: 10.1136/gut.25.9.988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dye M., MacDonald A., Smith G. The bacterial flora of the biliary tract and liver in man. Br J Surg. 1978 Apr;65(4):285–287. doi: 10.1002/bjs.1800650419. [DOI] [PubMed] [Google Scholar]
  8. Flemma R. J., Flint L. M., Osterhout S., Shingleton W. W. Bacteriologic studies of biliary tract infection. Ann Surg. 1967 Oct;166(4):563–572. doi: 10.1097/00000658-196710000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fraisse H., Etaix J. P. Essai clinique de l'ampicilline injectable dans les affections hépato-biliaires en particulier. Lyon Med. 1966 Jan 30;215(5):271–277. [PubMed] [Google Scholar]
  10. Havig O., Hertzberg J. Effect of ampicillin, chloramphenicol, and penicillin-streptomycin in acute cholecystitis. Scand J Gastroenterol. 1973;8(1):55–58. [PubMed] [Google Scholar]
  11. Hirschmann J. V., Inui T. S. Antimicrobial prophylaxis: a critique of recent trials. Rev Infect Dis. 1980 Jan-Feb;2(1):1–23. doi: 10.1093/clinids/2.1.1. [DOI] [PubMed] [Google Scholar]
  12. Hoshino H., Onishi Y., Nameki K. [Clinical studies with amoxicillin in patients with biliary tract infections (author's transl)]. Jpn J Antibiot. 1977 Jan;30(1):121–123. [PubMed] [Google Scholar]
  13. Joiner K. A., Gorbach S. L. Acute septic complications in gastrointestinal emergencies. Clin Gastroenterol. 1981 Jan;10(1):93–106. [PubMed] [Google Scholar]
  14. Jones R. N., Fuchs P. C., Barry A. L., Gavan T. L., Sommers H. M., Gerlach E. H. Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin. Antimicrob Agents Chemother. 1980 Apr;17(4):743–749. doi: 10.1128/aac.17.4.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Keighley M. R., Drysdale R. B., Quoraishi A. H., Burdon D. W., Alexander-Williams J. Antibiotic treatment of biliary sepsis. Surg Clin North Am. 1975 Dec;55(6):1379–1390. doi: 10.1016/s0039-6109(16)40797-8. [DOI] [PubMed] [Google Scholar]
  16. Keighley M. R., Drysdale R. B., Quoraishi A. H., Burdon D. W., Alexander-Willians J. Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum. Gut. 1976 Jul;17(7):495–500. doi: 10.1136/gut.17.7.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kemmerich B., Lode H., Borner K., Belmega D., Jendroschek T., Koeppe P., Goertz G. Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother. 1983 Jul;12(1):27–37. doi: 10.1093/jac/12.1.27. [DOI] [PubMed] [Google Scholar]
  18. Kune G. A., Burdon J. G. Are antibiotics necessary in acute cholecystitis? Med J Aust. 1975 Oct 18;2(16):627–630. [PubMed] [Google Scholar]
  19. Levi J. U., Martinez O. V., Hutson D. G., Livingstone A., Zeppa R., Malinin T. I., Einhorn N. Ampicillin versus cefamandole in biliary tract surgery. A prospective, randomized clinical and bacteriological study. Am Surg. 1984 Aug;50(8):412–417. [PubMed] [Google Scholar]
  20. Mashimo K. Clinical experience with cefoperazone in biliary tract infections. Drugs. 1981;22 (Suppl 1):100–107. doi: 10.2165/00003495-198100221-00021. [DOI] [PubMed] [Google Scholar]
  21. Mendelson J., Portnoy J., Sigman H. Pharmacology of gentamicin in the biliary tract of humans. Antimicrob Agents Chemother. 1973 Nov;4(5):538–541. doi: 10.1128/aac.4.5.538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mortimer P. R., Mackie D. B., Haynes S. Ampicillin levels in human bile in the presence of biliary tract disease. Br Med J. 1969 Jul 12;3(5662):88–89. doi: 10.1136/bmj.3.5662.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mueller O., Fabricius K., Krueger E., Rueckert U. Pharmacokinetics and clinical efficacy of moxalactam in biliary tract infections. Rev Infect Dis. 1982 Nov-Dec;4 (Suppl):S688–S691. doi: 10.1093/clinids/4.supplement_3.s688. [DOI] [PubMed] [Google Scholar]
  24. Nakamura T., Hashimoto I., Sawada Y., Mikami J., Bekki E., Hirasawa S., Abe H., Watanabe Y. Cefoperazone concentrations in bile and gall bladder wall after intravenous administration. Antimicrob Agents Chemother. 1980 Dec;18(6):980–982. doi: 10.1128/aac.18.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Paulet P. Cefazolin in the treatment of biliary tract infections. Acta Gastroenterol Belg. 1976 Jul-Aug;39(7-8):293–297. [PubMed] [Google Scholar]
  26. Pitt H. A., Roberts R. B., Johnson W. D., Jr Gentamicin levels in the human biliary tract. J Infect Dis. 1973 Mar;127(3):299–302. doi: 10.1093/infdis/127.3.299. [DOI] [PubMed] [Google Scholar]
  27. Ram M. D., Gharavi M. A. Biliary infections and the chouce of antibiotics. Am J Gastroenterol. 1974 Aug;62(2):134–138. [PubMed] [Google Scholar]
  28. Saharia P. C., Cameron J. L. Clinical management of acute cholangitis. Surg Gynecol Obstet. 1976 Mar;142(3):369–372. [PubMed] [Google Scholar]
  29. Scott A. J., Khan G. A. Origin of bacteria in bileduct bile. Lancet. 1967 Oct 14;2(7520):790–792. doi: 10.1016/s0140-6736(67)92231-3. [DOI] [PubMed] [Google Scholar]
  30. Smith C. R., Lipsky J. J. Hypoprothrombinemia and platelet dysfunction caused by cephalosporin and oxalactam antibiotics. J Antimicrob Chemother. 1983 Jun;11(6):496–499. doi: 10.1093/jac/11.6.496. [DOI] [PubMed] [Google Scholar]
  31. Smith C. R., Lipsky J. J., Laskin O. L., Hellmann D. B., Mellits E. D., Longstreth J., Lietman P. S. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980 May 15;302(20):1106–1109. doi: 10.1056/NEJM198005153022002. [DOI] [PubMed] [Google Scholar]
  32. Thompson J. E., Jr, Tompkins R. K., Longmire W. P., Jr Factors in management of acute cholangitis. Ann Surg. 1982 Feb;195(2):137–145. doi: 10.1097/00000658-198202000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Truchot M. R. La Gentamycine injectable en pathologie hépato-bilaire et digestive. J Med Lyon. 1968 Mar 20;49(139):537–539. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES